Is it safe to prescribe losartan for a patient with stage 2 chronic kidney disease and diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, losartan is appropriate and recommended for CKD stage 2 with diabetes

Losartan (an ARB) is specifically indicated for diabetic nephropathy in patients with type 2 diabetes and is safe to use in CKD stage 2. 1 The FDA label explicitly states losartan is indicated "for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension" and has been shown to reduce progression of nephropathy. 1

Guideline-Based Recommendations

The 2022 KDIGO guidelines strongly support ARB use in this population:

  • An ACE inhibitor or ARB is recommended for patients with diabetes who have hypertension and albuminuria, titrated to the maximum tolerated dose 2, 3
  • This applies to both type 1 and type 2 diabetes with CKD 3
  • ARBs should be used as part of a comprehensive treatment plan alongside SGLT2 inhibitors, statins, and other evidence-based therapies 2, 3

CKD Stage 2 Considerations

CKD stage 2 (eGFR 60-89 mL/min/1.73 m²) is well within the safe range for losartan initiation:

  • No dose adjustment is needed at this level of kidney function
  • The landmark RENAAL trial demonstrated losartan reduced the risk of doubling serum creatinine by 25% and end-stage renal disease by 28% in diabetic nephropathy 4
  • Benefits exceeded those attributable to blood pressure reduction alone 4

Critical Monitoring Requirements

Monitor serum creatinine and potassium within 2-4 weeks after starting losartan: 2

  • Continue losartan if creatinine rises <30% - this is expected hemodynamic effect 2
  • Stop or reduce dose if creatinine rises >30% - evaluate for acute kidney injury, volume depletion, or renal artery stenosis 2
  • Manage hyperkalemia medically rather than stopping losartan immediately - adjust diet, correct volume depletion, review concurrent medications (NSAIDs, potassium supplements) 2

Important Caveats

Absolute contraindications:

  • Pregnancy or women planning pregnancy 1
  • Concurrent use with aliskiren (direct renin inhibitor) in diabetic patients 1
  • Do NOT combine with an ACE inhibitor - use only one RAS blocker 2

Relative cautions requiring dose adjustment or discontinuation:

  • Symptomatic hypotension 2
  • Uncontrolled hyperkalemia despite medical management 2
  • Volume depletion (from vomiting, diarrhea) - correct first 1

Practical Implementation

Start losartan 50 mg daily, can increase to 100 mg daily based on blood pressure response and tolerability. 1 The typical maintenance dose in diabetic nephropathy is 50-100 mg once daily. 1

Concurrent medications to optimize:

  • Add an SGLT2 inhibitor (strongly recommended for CKD stage 2, eGFR ≥20) 2, 3
  • Continue or initiate a statin 3
  • Consider adding a GLP-1 receptor agonist if not at glycemic target 3

The evidence strongly supports losartan use in this clinical scenario, with proven renal and cardiovascular benefits that extend beyond blood pressure control. 4, 5

References

Related Questions

Is it safe to prescribe losartan to an adult with diabetes and chronic kidney disease stage 3?
For a 54-year-old woman with type 2 diabetes, hypertension, hypercholesterolemia, chronic kidney disease on dialysis, who presented with acute upper gastrointestinal bleeding, received one unit of packed red blood cells, and had an esophagogastroduodenoscopy showing a clean base, what post‑discharge medication regimen should be recommended?
In a 72-year-old man with type 2 diabetes mellitus, hypertension, and atrial fibrillation who has chronic kidney disease with eGFR 34 mL/min/1.73 m², elevated urine albumin-to-creatinine ratio (10.7 mg/mmol), proteinuria, hematuria, leukocyturia, A1C 6.8%, and creatinine 182 µmol/L, what is the next step in management?
For a 59-year-old, 123‑kg man with type 2 diabetes (creatinine 0.84 mg/dL, eGFR > 90 mL/min) currently on U‑500 regular insulin (115 U at breakfast, 115 U at lunch, 50 U at dinner) and receiving dexamethasone 10 mg at 16:00 and 6 mg at 14:30, what NPH (intermediate‑acting) insulin dose should be added and how should the U‑500 insulin doses be adjusted?
What is the next best step in managing a 72-year-old man with type 2 diabetes, hypertension, chronic kidney disease (estimated glomerular filtration rate 42 mL/min/1.73 m²), on insulin glargine (Lantus) 34 U in the morning and 24 U in the evening, whose HbA1c increased from 8.1% to 8.8% and who cannot afford semaglutide (Ozempic) or dapagliflozin (Farxiga)?
What is the appropriate treatment for a 73-year-old patient with moderate right lower lobe infiltrates on chest X‑ray?
What are the symptoms of diverticulitis in a patient with a history of scattered diverticula?
Are dizziness and drowsiness within the first two hours common side effects of zolmitriptan 2.5 mg?
Can bacitracin be used to treat a Pseudomonas aeruginosa infection (e.g., in the ear canal)?
What mild side effects can occur with zolmitriptan 2.5 mg, and are speech‑finding disorders (aphasia or apraxia of speech) among them?
A 68‑inch‑tall male weighing 194 lb with a BMI of 29.5—is he considered morbidly obese?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.